sls009
sls009: sourced relationships with 1 company · 1 clinical trial tracked.
sls009 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could sls009 → SLS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | Phase 1/Phase 2 |
Clinical Trial Registry Records (1)
A Phase I/IIa, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent and in Combination With Venetoclax and Azacitidine in Patients With Relapsed/Refractory Hematologic Malignancies and High-Risk Newly Diagnosed AML
Primary endpoint: Safety and Tolerability: Dose Limiting Toxicities (DLTs)
Frequently asked questions
Which companies have sourced relationships with sls009?
sls009 has dated SEC/FDA relationship records for SELLAS Life Sciences Group, Inc..
How many clinical trials involve sls009?
BioSniper tracks 1 clinical trial involving sls009.